Don't understand why anyone would sell this for under 2 million MC - the EV of all of AGX's ventures is effectively valued by the market at a big fat ZERO
Some facts about AGX (from its last preso)
? ThromboView : For Blood Clot Diagnosis. Phase III ready. $38.5m capital has been expended on development and Phase 1 and 2 human trials. Currently AGX is looking for a partner and it has been looking since october last year
- DiagnostIQ: point of care rapid diagnostic platform can be partnered for multiple tests. AGX is partnered with Arrayjet Limited (Scotland) to develop microarray platform
- Directors hold 22% of shares
- Very low cash burn rate for a biotech in phase 3 (anyone have a figure on the costs for phase 3?)
-Top 20 shareholders hold 64.8% of shares
Extremely frustrated that I entered at 1.7 and then got sh*t out minutes later. Ideally would have gotten stopped out but fundamentals seem nice so I guess this is one of the failed-STT-becoming medium term holds LOL.
cash flow, page-21
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 26523991 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 1564360 | 5 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| CT1 (ASX) Chart |
Day chart unavailable